| Target Price | €18.26 |
| Price | €16.90 |
| Potential |
8.04%
register free of charge
|
| Number of Estimates | 16 |
|
16 Analysts have issued a price target OTE Group 2026 .
The average OTE Group target price is €18.26.
This is
8.04%
register free of charge
€24.15
42.90%
register free of charge
€15.66
7.37%
register free of charge
|
|
| A rating was issued by 19 analysts: 12 Analysts recommend OTE Group to buy, 6 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the OTE Group stock has an average upside potential 2026 of
8.04%
register free of charge
|
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion € | 3.59 | 3.55 |
| 3.51% | 1.11% | |
| EBITDA Margin | 38.17% | 40.24% |
| 4.19% | 5.42% | |
| Net Margin | 13.33% | 17.08% |
| 13.01% | 28.09% |
14 Analysts have issued a sales forecast OTE Group 2025 . The average OTE Group sales estimate is
This results in the following potential growth metrics:
14 Analysts have issued an OTE Group EBITDA forecast 2025. The average OTE Group EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
14 OTE Group Analysts have issued a net profit forecast 2025. The average OTE Group net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share € | 1.16 | 1.50 |
| 7.94% | 29.31% | |
| P/E | 11.27 | |
| EV/Sales | 2.07 |
14 Analysts have issued a OTE Group forecast for earnings per share. The average OTE Group EPS is
This results in the following potential growth metrics and future valuations:
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


